Literature DB >> 23784934

Exogenous hydrogen sulfide prevents kidney damage following unilateral ureteral obstruction.

Dapeng Jiang1, Yubo Zhang, Mowen Yang, Shuai Wang, Zhitao Jiang, Zhaozhu Li.   

Abstract

AIMS: To investigate the protective effects of exogenous hydrogen sulfide (H2 S) against unilateral ureteric obstruction (UUO) induced renal injury and explore the potential mechanisms involved.
METHODS: Rats were randomly divided into four groups: sham group, UUO group, UUO + saline group, and UUO + NaHS group. Rats were sacrificed on Day 10 after UUO. The tubulointerstitial injury, interstitial fibrosis, and the infiltrating of macrophages in the interstitium were assessed. Expression of TNF-α in kidney tissue was also measured. Oxidative stress was evaluated by detecting the level of MDA and SOD in renal tissues.
RESULTS: Interstitial fibrosis and renal injury score were markedly increased on Day 10 after UUO. In contrast, administration of NaHS significantly reduced the injury score. In addition, the kidneys that were treated with NaHS exhibited minimal interstitial fibrosis. The number of ED1 positive cells in the interstitium and the level of TNF-α were significantly higher in UUO kidneys compared with that in sham group. NaHS treatment significantly attenuated infiltration of macrophages and the expression of TNF-α. Our findings showed a significant increase in MDA level and decrease in the SOD activity in the UUO group compared to the sham group. However, significant decrease in MDA level and increase in SOD activity were observed after treatment of NaHS.
CONCLUSIONS: Our study demonstrates that NaHS protects against UUO-induced renal damage via attenuating fibrosis, oxidative stress, and inflammation. Therefore, H2 S may be useful as a potential candidate in the treatment of renal damage induced by obstruction. Neurourol. Urodynam. 33:538-543, 2014.
© 2013 Wiley Periodicals, Inc. © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  hydrogen sulfide; inflammation; interstitial fibrosis; oxidative stress; unilateral ureteral obstruction

Mesh:

Substances:

Year:  2013        PMID: 23784934     DOI: 10.1002/nau.22450

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  7 in total

Review 1.  Hydrogen Sulfide as a Potential Therapeutic Target in Fibrosis.

Authors:  Shufang Zhang; Chuli Pan; Feifei Zhou; Zhi Yuan; Huiying Wang; Wei Cui; Gensheng Zhang
Journal:  Oxid Med Cell Longev       Date:  2015-05-11       Impact factor: 6.543

Review 2.  The Role of Hydrogen Sulfide in Renal System.

Authors:  Xu Cao; Jin-Song Bian
Journal:  Front Pharmacol       Date:  2016-10-18       Impact factor: 5.810

Review 3.  Involvement of hydrogen sulfide in the progression of renal fibrosis.

Authors:  Yu Wang; Qi-Qi Xing; Jing-Ke Tu; Wen-Bin Tang; Xiang-Ning Yuan; Yan-Yun Xie; Wei Wang; Zhang-Zhe Peng; Ling Huang; Hui Xu; Jiao Qin; Xiang-Cheng Xiao; Li-Jian Tao; Qiong-Jing Yuan
Journal:  Chin Med J (Engl)       Date:  2019-12-05       Impact factor: 2.628

Review 4.  Roles of Hydrogen Sulfide Donors in Common Kidney Diseases.

Authors:  Ebenezeri Erasto Ngowi; Muhammad Sarfraz; Attia Afzal; Nazeer Hussain Khan; Saadullah Khattak; Xin Zhang; Tao Li; Shao-Feng Duan; Xin-Ying Ji; Dong-Dong Wu
Journal:  Front Pharmacol       Date:  2020-11-19       Impact factor: 5.810

Review 5.  The roles of hydrogen sulfide in renal physiology and disease states.

Authors:  Jianan Feng; Xiangxue Lu; Han Li; Shixiang Wang
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

6.  Protective effect of hydrogen sulfide on renal injury in the experimental unilateral ureteral obstruction.

Authors:  Murat Dursun; Alper Otunctemur; Emin Ozbek; Suleyman Sahin; Huseyin Besiroglu; Ozgur Doga Ozsoy; Mustafa Cekmen; Adnan Somay; Nurver Ozbay
Journal:  Int Braz J Urol       Date:  2015 Nov-Dec       Impact factor: 1.541

7.  Protective effect of H2S on LPS‑induced AKI by promoting autophagy.

Authors:  Ting Li; Jie Zhao; Shuying Miao; Yiyang Chen; Yunfei Xu; Ying Liu
Journal:  Mol Med Rep       Date:  2022-01-21       Impact factor: 2.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.